A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI)

Trial Profile

A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Nerispirdine (Primary)
  • Indications Spinal cord injuries
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Apr 2014 New trial record
    • 18 Jul 2006
    • 28 Sep 2005
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top